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Objective: Insulin-like growth factor 1 has been shown to be cytoprotective against
ischemia-reperfusion injury in various organs. However, spinal cord protection by
insulin-like growth factor 1 has not been tested. We have therefore examined the effect
of insulin-like growth factor 1 on neuronal cell death and motor function after spinal
cord ischemia.
Methods: Japanese white rabbits were subjected to spinal cord ischemia by clamp-
ing the abdominal aorta for 15 minutes. Insulin-like growth factor 1 (0.3 mg/kg) at
a dose equipotent to insulin (0.3 IU/kg) in lowering blood glucose level or the con-
trol (phosphate-buffered saline solution as a vehicle) was administered intra-
venously 30 minutes before the aortic clamp.
Results: Hind-limb motor function had recovered normally 48 hours after the opera-
tion in all the rabbits (n = 8) treated with insulin-like growth factor 1. In contrast, all
the control-treated (n = 8) and all but one of the insulin-treated (n = 6) rabbits had dete-
riorated to paraplegia by 48 hours after the operation. Histopathologic sections in the
involved spinal cord segment showed that a significantly (P < .0001) greater number
of motor neuron cells were preserved in the rabbits treated with insulin-like growth fac-
tor 1 (17.9 ± 4.8 per section) than in those treated with the control (8.0 ± 2.1). Although
insulin was equipotent to insulin-like growth factor 1 in preserving the number of
motor neuron cells (18.5 ± 2.7), the percentage of motor neuron cells positive for ter-
minal deoxynucleotidyltransferase–mediated deoxyuridine triphosphate-biotin nick-
end labeling were significantly (P < .01) smaller in the rabbits treated with insulin-like
growth factor 1 (6.0 ± 4.6) compared with those treated with the control (54.6 ± 33.8)
and insulin (26.2 ± 11.7). Immunohistochemical studies revealed that insulin-like
growth factor 1 increased expression of the antiapoptotic Bcl-xL protein and inhibited
expression of the proapoptotic Bax protein in motor neuron cells 24 and 48 hours after
the operation. In contrast, expression of only Bax was increased after the operation in
other groups of rabbits subjected to spinal cord ischemia.
Conclusions: These results suggest that insulin-like growth factor 1, but not insulin
with a conventional dose, protects motor neuron cells from ischemic spinal cord
injury associated with differential regulation of Bcl-xL and Bax protein. 
Paraplegia remains a major devastating complication after operationsfor thoracoabdominal aortic aneurysm.1,2 Strategies avoidingischemic spinal cord injury have been a subject for extensive investi-gation. Because identification of the Adamkiewicz artery and itsselective reconstruction are difficult in the majority of cases, mechan-ical and pharmacologic interventions have been attempted to reduce
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the incidence of perioperative paraplegia. However, despite
numerous efforts, none of the procedures have been proven
to be consistently effective in preventing paraplegia.3
The unique feature of ischemic spinal cord injury is the
occurrence of delayed-onset paraplegia. The delayed-onset
paraplegia can be induced after a relatively brief period of
spinal cord ischemia in the rabbit model by crossclamping
of the abdominal aorta. Studies have demonstrated progres-
sive loss of motor neurons accompanied with a steady
decline of motor function.4-6 More recently, it has been
shown that the form of death in motor neuron cells subject-
ed to spinal cord ischemia is not only necrosis but also
apoptosis,7,8 which may be a mechanism of the delayed
onset of neuronal cell death.
Although life and death of the cell is determined by a
number of intracellular events, Bcl-2 family proteins play a
pivotal role in the death regulatory process. Bax is involved
in the induction phase of cell death, whereas Bcl-2 and Bcl-
xL are known to counteract the death-promoting action of
Bax.9-11 A significant correlation between the level of Bcl-2
family proteins and the severity of infarction after ischemia
has been reported in the heart and the brain.12-15 Thus, phar-
macologic interventions that induce up-regulation of anti-
apoptotic Bcl-2 family proteins and down-regulation of
proapoptotic Bcl-2 family proteins could represent a
promising approach for prevention of paraplegia.
Insulin-like growth factor 1 (IGF-1) is a local effector of
growth hormone and has a structural similarity to proinsulin
and functional similarity to insulin.16,17 IGF-1 has been
shown to provide cytoprotection against neuronal cells and
myocytes subjected to ischemia and reperfusion.18,19 Recent
studies indicate that Bcl-2 family proteins may be effector
molecules responsible for IGF-1–induced cytoprotection.20-22
Therefore, we have examined the effect of IGF-1 and insulin
on motor functions and neuronal cell death after spinal cord
ischemia in relation to the expression of Bcl-2 family pro-
teins.
Materials and Methods
Surgical Preparation
Japanese white rabbits weighing 2.5 to 3.5 kg were anesthetized
with 1.0% halothane and 99% oxygen. Animals were placed in the
supine position and allowed to breath spontaneously without
mechanical ventilation. A 24-gauge venous catheter was placed in
the marginal ear vein, and cefamandole (50 mg/kg) was adminis-
tered as a single dose. A 22-gauge arterial catheter was placed in
the central ear artery. Arterial pressure and rectal temperature were
monitored continuously. A heating pad was placed under the rab-
bit to maintain rectal temperature at 37°C to 38°C. After the rabbit
had been stabilized, a median laparotomy was performed. The
abdominal aorta was dissected just caudal to the left renal artery
and above the bifurcation of the aorta. After systemic anticoagula-
tion with intravenous injection of heparin sulfate (200 U/kg), a 20-
gauge catheter was introduced over a guide wire from the right
femoral artery to the abdominal aorta. The tip of the femoral artery
catheter was placed 5 mm above the bifurcation of the aorta to
monitor aortic arterial pressure of the clamped segment. Spinal
cord ischemia was introduced by clamping of the aorta at 3 points,
the abdominal aorta just caudal to the left renal artery, the posteri-
or mesenteric artery, and the bifurcation of the aorta, for 15 min-
utes. The bifurcation of the aorta was clamped with a snare so as
not to occlude the femoral artery catheter, and the other 2 points
were crossclamped with surgical microclamps. The snare and the
aortic crossclamps were removed after 15 minutes, and the
abdomen was closed in 2 layers. After the operations, all the rab-
bits were returned to their cages and allowed free access to water
and food. Animal care and experiments complied with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published  by the National Academy Press, revised
1996.
Experimental Groups
Eight rabbits received IGF-1 (0.3 mg/kg), 6 rabbits received
insulin (0.3 IU/kg), and 8 rabbits received 1 mL of phosphate-
buffered saline solution intravenously as the vehicle control 30
minutes before the aortic clamping. Five rabbits of the sham-oper-
ated group underwent laparotomy, and the aorta was dissected as
described above without aortic clamping. IGF-1 was a generous
gift from Fujisawa Pharmaceutical Co Ltd (Osaka, Japan). Insulin
(human recombinant) was obtained from Wako Pure Chemical
Industries Ltd (Osaka, Japan). The doses of IGF-1 and insulin used
in the present study were determined according to the guidelines of
clinical use of IGF-1 published by Fujisawa Pharmaceutical Co
Ltd in 1995. The doses of IGF-1 and insulin were equipotent with
respect to glucose metabolism, and increasing the doses 5 times
resulted in lethal hypoglycemia in some animals.
Neurologic Assessment
Hind-limb motor function was scored at 6, 24, and 48 hours after
the operation by using the modified Tarlov scale23 (0 = no move-
ment; 1 = slight movement; 2 = sits with assistance; 3 = sits alone;
4 = weak hop; 5 = normal hop). Two observers (one of whom was
blinded to the experimental conditions) graded the neurologic sta-
tus independently.
Histopathologic Examination and Terminal
Deoxynucleotidyltransferase–Mediated Deoxyuridine
Triphosphate-Biotin Nick-End Labeling
All rabbits underwent laparotomy 48 hours after the first operation.
As soon as the abdominal aorta was clamped as described above,
the animals were anesthetized with an intravenous injection of a
lethal dose of sodium pentobarbital (200 mg/kg) and heparin sul-
fate (200 U/kg), and the spinal cord was perfusion fixed with 10%
formaldehyde through the femoral artery catheter placed within the
clamped aorta. The lumbar spinal cord was removed, fixed for 2
weeks in the same fixative, and embedded in paraffin. Transverse
sections were cut to a thickness of 4 µm at the level of L6. The sec-
tions were stained with hematoxylin and eosin for histopathologic
observations. For quantification of the number of motor neuron
cells, motor anterior horn cells were counted in 3 sections at a
magnification of 400×, and the values were averaged.
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The serial sections were analyzed for motor neuron cell apopto-
sis by using a terminal deoxynucleotidyltransferase-mediated
deoxyuridine triphosphate-biotin nick-end labeling (TUNEL)
method with Apop Tag (Oncor Inc, Gaithersburg, Md). TUNEL-
positive motor anterior horn cells were counted in 3 sections at a
magnification of 200×, and the percentage of TUNEL-positive
motor neuron cells was calculated.
Immunohistochemical Staining for Bcl-2 Family
Proteins
The sections were placed in a glass jar filled with 10 mmol/L cit-
rate buffer (pH 6.0) and exposed to a 500-W microwave for 5 min-
utes twice. The sections were incubated in absolute methanol con-
taining 0.3% hydrogen peroxide for 30 minutes, and nonspecific
binding was blocked with normal goat serum. The sections were
then incubated overnight at 4°C with the primary antibodies (rab-
bit polyclonal anti-Bcl-2 antibodies, rabbit polyclonal anti-Bcl-
xS/L antibodies, or rabbit polyclonal anti-Bax antibodies) at 1:20
dilution. These antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, Calif). Afterward, the slides were
washed with phosphate-buffered saline solution and incubated
with fluorescein isothiocyanate–conjugated or tetrarhodamine
isothiocyanate–conjugated goat anti-rabbit F(ab´)2 immunoglobu-
lin IgG (Zymed Laboratories, Inc, San Francisco, Calif) at a 1:100
dilution for 1 hour at room temperature. The fluorescence staining
was visualized with confocal laser microscopy (Fluoview;
Olympus, Tokyo, Japan) at a magnification of 600×.
Statistical Analysis
Statistical analysis of the neurologic scores was performed with
the nonparametric Mann-Whitney U test. All other data are pre-
sented as means ± SD. One-way analysis of variance and the
Scheffé multiple comparison test were used to compare the multi-
group variables.
Results
Blood Glucose Level
Blood glucose levels immediately before injection of IGF-1
or insulin were not significantly different from those in the
time-matched, sham-operated rabbits or the control rabbits
(Figure 1). However, blood glucose levels were significant-
ly lowered in the IGF-1–treated and insulin-treated rabbits
compared with the sham-operated and control rabbits. The
peak decline of blood glucose levels was observed at 15
minutes after aortic clamping in both the IGF-1–treated and
insulin-treated rabbits. The magnitude of decline of blood
glucose levels was similar between the IGF-1–treated and
insulin-treated rabbits 15 minutes after aortic clamping and
30 minutes after aortic declamping.
Neurologic Assessment
The sham-operated rabbits showed no neurologic deficit
during a 48-hour observation period. Paraplegia (score 0)
developed in 4 of 8 rabbits in the control group within 6
hours after the operation (Table 1). The condition of the
other 2 rabbits and the rest of the rabbits in the control group
had deteriorated to paraplegia by 24 and 48 hours after the
operation, respectively. In contrast, all the rabbits treated
with IGF-1 maintained hind-limb motor function scores of
4 or 5 for 48 hours after the operation. Although 2 of 6 rab-
bits treated with insulin maintained hind-limb motor func-
tion scores of 4 or 5 for 48 hours after the operation, para-
plegia developed within 24 hours after the operation in the
other 4 rabbits. Consequently, the IGF-1 but not the insulin
treatment significantly improved neurologic function at any
given observation period compared with that of the control
rabbits.
Histopathologic Examination
No sign of spinal cord damage was observed in hematoxylin
and eosin–stained sections in the sham-operated rabbits
(Figure 2, upper panel). However, in the control rabbits the
Figure 1. Blood glucose levels in the sham-operated (n = 5, open
bars), control (n = 8, shaded bars), IGF-1–treated (n = 8, hatched
bars), and insulin-treated (n = 6, filled bars) rabbits. *P < .01 com-
pared with control rabbits. Ao, Aortic.
TABLE 1 Effect of insulin-like factor-1 (IGF-1) and insulin on
hind-limb motor function
Control (n = 8) IGF-1 (n = 8) Insulin (n = 6)
Tarlov score 6 h 24 h 48 h 6 h* 24 h† 48 h† 6 h 24 h 48 h
0 4 6 8 0 0 0 3 4 4
1 1 2 0 0 0 0 2 0 0
2 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0
4 1 0 0 2 1 1 0 1 1
5 2 0 0 6 7 7 1 1 1
Hind-limb motor function was assessed by Tarlov score as described
in the “Materials and methods.”
*P  > .05 compared with control.
†P > .01 compared with control.
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segment that had been subjected to spinal cord ischemia
showed severe neuronal damage, as evidenced by reduced
numbers of motor neuron cells, disappearance of Nissl bod-
ies and nuclei in the remaining motor neuron cells, and vac-
uolation of gray matter. In contrast, the rabbits treated with
IGF-1 showed almost intact-looking light microscopic find-
ings of the involved spinal cord segment. The rabbits treat-
ed with insulin showed microscopic abnormalities in the
involved spinal cord segment similar to those observed in
the control rabbits, although the number of motor neuron
cells was preserved.
Quantitative analysis showed that the number of motor
neuron cells in the involved spinal cord segment in the rab-
bits treated with IGF-1 and insulin was comparable with
that in the sham-operated rabbits and was significantly (P <
.0001) greater than that in the control rabbits (Figure 2,
lower panel).
TUNEL staining
Very few TUNEL-positive motor neuron cells were found in
the motor anterior horn in the sham-operated rabbits (Figure
3). The percentage of TUNEL-positive motor neuron cells
was markedly increased in the motor anterior horn of the
involved spinal cord segment 48 hours after spinal cord
ischemia in the control rabbits. In contrast, the percentage of
TUNEL-positive motor neuron cells was significantly (P <
.01) reduced by treatment with IGF-1. Although the insulin
treatment tended (P < .1) to inhibit the emergence of
TUNEL-positive motor neuron cells compared with that in
control-treated rabbits, this inhibition was incomplete, and
IGF-1 was significantly (P < .001) more effective in reduc-
ing the number of TUNEL-positive motor neuron cells than
was insulin.
Expression of Bcl-xL and Bax
We examined whether IGF-1–induced inhibition of apopto-
sis is associated with enhanced expression of antiapoptotic
Bcl-2 family proteins, attenuated expression of proapoptot-
ic Bcl-2 family proteins, or both. We focused on Bcl-xL and
Bax because these two proteins are known to play a pivotal
role in neuronal development and neuronal cell death in
postnatal life.24,25 Expressions of Bcl-xL and Bax in motor
neuron cells was not immunohistochemically detectable in
the sham-operated rabbits (Figure 4). However, expression
Figure 2. Hematoxylin and eosin staining of the spinal cord segment (L6) 48 hours after spinal cord ischemia
(upper panel; original magnification 400×). The number of motor neuron cells in the motor anterior horn per sec-
tion (lower panel) is shown in the sham-operated group (n = 5), the control group (n = 8), the IGF-1–treated group
(n = 8), and the insulin-treated group (n = 6). *P < .0001 compared with the control group.
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of only Bax was increased in the majority of motor neuron
cells in the involved spinal cord segment in the control rab-
bits 24 and 48 hours after spinal cord ischemia. In contrast,
expression of only Bcl-xL was increased in the majority of
motor neuron cells in the involved spinal cord segment in
the rabbits treated 24 and 48 hours after the operation with
IGF-1. The insulin treatment modestly increased Bcl-xL
and inhibited Bax expression 24 hours after spinal cord
ischemia, but only Bax expression was elevated 48 hours
after the operation. Bcl-2 was undetectable in motor neuron
cells after any treatment modality (not shown). Similar
results with respect to Bcl-xL, Bax, and Bcl-2 expressions
were observed in all the rabbits of each experimental group.
Discussion
The present study provides the evidence for the first time
that intravenous administration of IGF-1, but not insulin,
was capable of preventing paraplegia after spinal cord
ischemia. Development of paraplegia was associated with
morphologic deterioration and the loss of motor neuron
cells and the emergence of TUNEL-positive motor neuron
cells in the spinal cord segment subjected to ischemia. The
treatment with IGF-1 preserved hind-limb motor function,
morphologic integrity, and the number of motor neuron cells
and inhibited the emergence of TUNEL-positive motor neu-
ron cells. In contrast, the insulin treatment was not effective
in reversing the loss of hind-limb motor function. Although
insulin preserved the number of motor neuron cells 48 hours
after the operation at levels comparable with those of IGF-
1, it failed to prevent morphologic deterioration and apopto-
sis of motor neuron cells. These findings suggest that the
effect of insulin treatment was only to delay motor neuron
cell death, and these cells ultimately died from apoptosis.
Although IGF-1 and insulin produce metabolically similar
effects on the cells, the mechanism of cytoprotection is quite
different. The doses of IGF-1 and insulin used in the present
study were equipotent in reducing blood glucose levels, indi-
cating that increased glucose metabolism is not a mechanism
of IGF-1–induced spinal cord protection. Instead, IGF-
1–induced inhibition of motor neuron cell death was associat-
ed with an increase in antiapoptotic Bcl-xL expression and
inhibition of proapoptotic Bax expression. Such a differential
Figure 3. TUNEL staining of the spinal cord segment (L6) 48 hours after spinal cord ischemia (upper panel; origi-
nal magnification 200×). Arrowhead, TUNEL-negative motor neuron cells; arrow, TUNEL-positive motor neuron
cells. Percentage of TUNEL-positive motor neuron cells in the motor anterior horn (lower panel) is shown in the
sham-operated group (n = 5), the control group (n = 8), the IGF-1–treated group (n = 8), and the insulin-treated group
(n = 6). *P < .01 compared with the control group. †P < .001 compared with the IGF-1 group.
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regulation of Bcl-2 family proteins was not appreciable 48
hours after the operation in the insulin-treated rabbits. It is
therefore suggested that differential regulation of Bcl-xL and
Bax expressions may be involved in the antineuronal cell
death effect of IGF-1. IGF-1 and insulin are known to provoke
common intracellular signaling pathways leading to up-regu-
lation of Bcl-xL and down-regulation of Bax. However, acti-
vation of this pathway by insulin should be much weaker than
IGF-1 at a dose mediating a comparable hypoglycemic effect
because glucose metabolism activity by insulin is approxi-
mately 30 times stronger than that of IGF-1. Increasing the
dose of insulin to the level equipotent to IGF-1 in promoting
the differential regulation of Bcl-xL and Bax could be effec-
tive in preventing paraplegia but may cause lethal hypo-
glycemia. It is thus proposed that the novel IGF-1 therapy, but
not a conventional glucose-insulin therapy, is required for pro-
tecting motor neuron cells from ischemic spinal cord injury.
It is now evident that the quantitative ratio of antiapoptotic
to proapoptotic Bcl-2 family proteins is crucial in determining
life and death of the cell. In the present study Bcl-2 was not
detected immunohistochemically in motor neuron cells after
any treatment modality, suggesting that Bcl-2 is not an
inducible major antiapoptotic protein after the IGF-1 treat-
ment in motor neuron cells. In contrast, Bax and Bcl-xL
expression was altered dramatically after ischemia and the
IGF-1 treatment but in an opposite way, suggesting the
importance of these Bcl-2 family proteins in regulating
motor neuron cell survival and death after spinal cord
ischemia. Although the present study does not provide a
causal relationship between the differential regulation of
Bcl-2 family proteins and spinal cord protection, the puta-
tive roles of Bcl-2 family proteins are consistent with the
hypothesis that up-regulation of Bcl-xL and down-regula-
tion of Bax by treatment with IGF-1 could promote the sur-
Figure 4. Immunohistochemical staining for Bcl-xL (green fluorescence) and Bax (red fluorescence) in the spinal
cord segment (L6) 24 and 48 hours after spinal cord ischemia. The fluorescence staining was visualized with con-
focal laser microscopy at a magnification of 600×. No appreciable expression of Bcl-xL and Bax was observed in
motor neuron cells in the sham-operated rabbits. Expression of only Bax was increased in motor neuron cells in
the control rabbits 24 and 48 hours after spinal cord ischemia. Treatment with IGF-1 increased expression of Bcl-
xL in motor neuron cells, with no appreciable expression of Bax 24 and 48 hours after spinal cord ischemia.
Treatment with insulin modestly increased Bcl-xL and inhibited Bax expression 24 hours after spinal cord
ischemia, but only Bax expression was elevated 48 hours after the operation.
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vival of motor neuron cells after ischemic spinal cord
injury. Figure 5 depicts the proposed mechanism of IGF-
1–induced spinal cord protection. Spinal cord ischemia and
reperfusion increase excitatory amino acids in the proxim-
ity of neuronal cell membranes that stimulates N-methyl-D-
aspartate and non–N-methyl-D-aspartate receptors. These
receptors,26 in conjunction with other mechanisms, such as
Na+/H+ exchange–mediated27 increase in intracellular
Ca2+, stimulates the synthesis of oxygen-derived free radi-
cals and nitric oxide.28,29 The increase in intracellular Ca2+,
oxygen-derived free radicals, and nitric oxide opens the
mitochondrial permeability transition pore. Permeability
transition pore is a large-conductance, cyclosporine (INN:
ciclosporin)–inhibitable channel in the inner membrane of
mitochondria.30 Permeability transition–pore opening
causes dissipation of H+ gradient across the membrane. The
loss of electrochemical gradient results in uncoupling of
the respiratory chain and subsequent abrogation of adeno-
sine triphosphate synthesis by means of F0-F1 adenosine
triphosphatase. Depriving the cell of adenosine triphos-
phate is a primary step for necrosis. Permeability transi-
tion–pore opening, on the other hand, is associated with the
release of cytochrome c and apoptosis-inducing factor from
mitochondria.31 Cytochrome c released into cytosol can
activate a cysteine protease (caspase) cascade, leading to
apoptosis in the presence of Apaf-1 and deoxyadenosine
triphosphate.32 Bcl-2 family proteins, which reside abun-
dantly in the outer membrane of mitochondria, are thought
to regulate permeability transition–pore opening.31-34 Bcl-
xL interferes with mitochondrial permeability transition–
pore opening, as well as with the release of cytochrome c
and apoptosis-inducing factor.35 Bax, on the contrary,
accelerates cytochrome c release by interacting with Bcl-
xL.36 Thus, Bcl-xL and Bax are critically involved in both
necrosis and apoptosis, and these two morphologically dis-
tinct forms of cell death could be prevented simultaneous-
ly by increasing the quantitative ratio of Bcl-xL and Bax in
mitochondria. Ischemia- and reperfusion-induced increase
in oxygen-derived free radicals and nitric oxide synthesis
are known to up-regulate Bax expression.37,38 On the con-
trary, IGF-1 treatment promotes up-regulation of Bcl-xL
and down-regulation of Bax,39,40 which could block all the
death signals arising from mitochondria downstream of
increases in intracellular Ca2+, oxygen-derived free radi-
cals, and nitric oxide. Indeed, in our study serial sections of
the spinal cord segment subjected to ischemia demonstrat-
ed that Bcl-xL–negative and Bax-positive motor neuron
cells underwent necrotic, as well as apoptotic, changes.
The loss of hind-limb motor function occurred within 6
hours after the operation in a considerable number of con-
trol rabbits and those treated with insulin. This finding indi-
cates that motor neuron dysfunction induced by ischemia
and reperfusion is not always mediated by delayed onset of
neuronal cell death but is also caused by acute neuronal cell
damage. Therefore, it is reasonable to assume that a part of
the benefit in spinal cord protection conferred by IGF-1 may
be unrelated to enhanced expression of Bcl-xL because the
synthesis of Bcl-xL protein may require at least hours after
the IGF-1 treatment. In this regard, our recent study41 with
the isolated and perfused rat heart model demonstrated that
IGF-1 treatment at the moment of reperfusion was effective
in improving left ventricular function and in inhibiting acute
necrotic cardiomyocyte cell death. Thus, the mechanism of
prevention of acute onset of neuronal cell injury by IGF-1
after spinal cord ischemia remains to be investigated.
In conclusion, bolus intravenous administration 30 min-
utes before spinal cord ischemia of IGF-1 at a dose equipo-
tent to insulin in reducing blood glucose level conferred sig-
nificant benefit in preventing paraplegia in the rabbit model.
Although the exact mechanism of neuronal cell protection
by IGF-1 remains to be clarified, circumstantial evidence
that the IGF-1 treatment enhanced the expression of anti-
apoptotic Bcl-xL protein and inhibited the expression of
proapoptotic Bax protein suggests that the differential regu-
lation of these death-regulatory proteins may be involved in
the mechanism of protection against delayed onset of neu-
ronal cell death and development of paraplegia.
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Figure 5. Proposed mechanism of IGF-I–induced spinal cord pro-
tection. (+) and (–) indicate stimulation and inhibition, respective-
ly. Dashed line indicates assault on mitochondria. NMDA, N-
methyl-D-aspartate; NHE, Na+/H+ exchange; Mt, mitochondria; cy.
c, cytochrome c; AIF, apoptosis-inducing factor.
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